Evaluation of efficacy and safety of targeted therapy and immune checkpoint inhibitors in metastatic colorectal cancer

doi:10.4251/wjgo.v17.i5.105027

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1459)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

HTML

622

Figures (1-3)

156

Tables (1-4)

153

Sum=986

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

253

Sum=352

Publishing Process of This Article

Item

Count

Browse

Download

Sum=70

May 15, 2025 (publication date) through Jun 26, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. May 15, 2025; 17(5): 105027
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.105027

Table 2 Assessment of treatment efficacy in patients with metastatic colorectal cancer receiving targeted therapy alone and combined targeted plus immunotherapy, n (%)

Best overall response	TT (n = 68)	TT + ICI (n = 31)	χ²	P value
CR	0	0	0	1
PR	10 (14.7)	5 (16.1)	-¹	1
SD	33 (48.5)	15 (48.4)	0	0.990
PD	25 (36.8)	11 (35.5)	0.015	0.902
ORR	10 (14.7)	5 (16.1)	-¹	1
DCR	43 (63.2)	21 (67.7)	0.189	0.664

¹Fisher's exact probability method.

TT: Targeted therapy; ICI: Immune checkpoint inhibitor; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ORR: Objective response rate; DCR: Disease control rate.

Citation: Wang PJ, Wang J, Yao XM, Cheng WL, Sun L, Yan J, Yu YL, Li SY, Li DP, Jia JH. Evaluation of efficacy and safety of targeted therapy and immune checkpoint inhibitors in metastatic colorectal cancer. World J Gastrointest Oncol 2025; 17(5): 105027
URL: https://www.wjgnet.com/1948-5204/full/v17/i5/105027.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i5.105027